37.21

1.48% -0.56

Hims Hers Health Inc (HIMS)

Overview News Price History Option Chain Financials Why HIMS Down? Discussions Forecast

Hims Hers Health Inc stock is traded at $37.21, with a volume of 10.24M. It is down -1.48% in the last 24 hours and down -4.64% over the past month. Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Previous Close:

$37.77

Open:

$37.6

24h Volume:

10.24M

Relative Volume:

0.39

Market Cap:

$8.47B

Revenue:

$1.78B

Net Income/Loss:

$164.40M

P/E Ratio:

53.93

EPS:

0.69

Net Cash Flow:

$236.51M

1W Performance:

-5.08%

1M Performance:

-4.64%

6M Performance:

-34.89%

1Y Performance:

+23.66%

1-Day Range:

$36.85

$38.88

1-Week Range:

$36.65

$40.74

52-Week Range:

$23.97

$72.98

Hims Hers Health Inc Stock (HIMS) Company Profile

Name

Hims Hers Health Inc

Sector

Healthcare (1123)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

415-851-0195

Address

2269 CHESTNUT ST, SAN FRANCISCO

Employee

1,637

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

HIMS's Discussions on Twitter

Compare HIMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIMS Hims Hers Health Inc	37.21	8.60B	1.78B	164.40M	236.51M	0.69
ZTS Zoetis Inc	118.66	51.85B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.33	45.46B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.52	42.70B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	29.79	34.62B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	493.99	21.03B	3.08B	1.24B	1.07B	25.61

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Oct-21-25	Initiated	KeyBanc Capital Markets	Sector Weight
Jun-23-25	Downgrade	Needham	Buy → Hold
Jun-04-25	Reiterated	Needham	Buy
Apr-29-25	Downgrade	TD Cowen	Buy → Hold
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-10-25	Downgrade	Citigroup	Neutral → Sell
Jan-07-25	Initiated	BTIG Research	Buy
Dec-17-24	Initiated	Morgan Stanley	Overweight
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral
Apr-16-24	Downgrade	Jefferies	Buy → Hold
Apr-10-24	Initiated	Canaccord Genuity	Buy
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform
Feb-26-24	Initiated	Leerink Partners	Market Perform
Dec-07-23	Initiated	Imperial Capital	In-line
Jul-28-23	Initiated	TD Cowen	Outperform
Apr-11-23	Initiated	Robert W. Baird	Neutral
Feb-09-23	Upgrade	Jefferies	Hold → Buy
Nov-08-22	Upgrade	BofA Securities	Neutral → Buy
Nov-08-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Oct-17-22	Downgrade	Piper Sandler	Overweight → Neutral
Sep-07-22	Initiated	Truist	Hold
Jul-15-22	Initiated	SVB Leerink	Underperform
Apr-14-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-10-22	Initiated	Deutsche Bank	Hold
Dec-02-21	Initiated	Jefferies	Hold
Nov-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Jul-06-21	Initiated	BofA Securities	Neutral
May-20-21	Upgrade	Credit Suisse	Neutral → Outperform
Apr-21-21	Initiated	Truist	Hold
Mar-09-21	Initiated	Credit Suisse	Neutral
Mar-02-21	Upgrade	Citigroup	Neutral → Buy
Feb-17-21	Initiated	Citigroup	Neutral
Feb-12-21	Initiated	Piper Sandler	Neutral
Feb-08-21	Initiated	Tigress Financial	Buy

View All

Hims Hers Health Inc Stock (HIMS) Latest News

Dec 12, 2025

Biomarker Testing Experiences - Trend Hunter

Dec 12, 2025

Hims & Hers Expands Weight-Management Program to the United Kingdom - Finviz

Dec 12, 2025

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance

Dec 12, 2025

Dec 11, 2025

Why Novo Nordisk Stock Topped the Market on Thursday - AOL.com

Dec 11, 2025

Hims & Hers targets UK’s weight loss market - eMarketer

Dec 11, 2025

Hims & Hers Expands Its Technology-Driven Personalized Virtual Care - The Globe and Mail

Dec 11, 2025

Hims & Hers Health's Options: A Look at What the Big Money is Thinking - Benzinga

Dec 11, 2025

Dec 10, 2025

Insider Sell Alert: Perez Garcia Andrea G Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus

Dec 10, 2025

Hims stock falls after lawmakers propose GLP-1 compounding restrictions By Investing.com - Investing.com Nigeria

Dec 10, 2025

High Short-Interest Stocks to Buy Before Q1 2026 - Investing.com

Dec 10, 2025

Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition? - Finviz

Dec 10, 2025

Hims & Hers Health (NYSE:HIMS) Earns Overweight Rating from Analysts at Barclays - MarketBeat

Dec 10, 2025

Hims & Hers launches weight loss program in UK with Hers platform - StreetInsider

Dec 10, 2025

Hims and Hers to offer weight-loss treatments in UK - Reuters

Dec 10, 2025

Dec 09, 2025

Does The Rally In Hims And Hers Health Still Leave Room For Growth In 2025 - Yahoo Finance

Dec 09, 2025

(HIMS) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com

Dec 09, 2025

What Analysts Think Is Changing the Hims and Hers Story for Long Term Investors - Yahoo Finance

Dec 09, 2025

Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell? - Finviz

Dec 09, 2025

Barclays Initiates Coverage on Hims & Hers Health (HIMS) with Ov - GuruFocus

Dec 09, 2025

5 High Short-Interest Stocks to Buy Before Q1 2026 - MarketBeat

Dec 09, 2025

XTX Topco Ltd Cuts Stock Holdings in Hims & Hers Health, Inc. $HIMS - MarketBeat

Dec 09, 2025

Barclays Initiates Hims & Hers Health With Overweight Rating, $48 Price Target - marketscreener.com

Dec 09, 2025

Hims & Hers' YourBio Health Acquisition: How They Are About To Revolutionize Blood Testing! - Smartkarma

Dec 09, 2025

Dec 08, 2025

Barclays Initiates Coverage of HIMS with Positive Outlook - GuruFocus

Dec 08, 2025

Andrew Dudum: 100 Most Influential People in Healthcare 2025 - Modern Healthcare

Dec 08, 2025

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance

Dec 08, 2025

Pharma company eyes Canada as patents lapse on weight-loss drugs - Benefits and Pensions Monitor

Dec 08, 2025

Truist Securities reiterates Hold rating on Hims and Hers stock amid soft Q4 trends - Investing.com UK

Dec 08, 2025

Divisadero Street Capital Management LP Sells 646,934 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat

Dec 08, 2025

Why Hims & Hers Stock Slipped Today - AOL.com

Dec 08, 2025

Dec 07, 2025

Promising Healthcare Stocks To Add to Your WatchlistDecember 7th - MarketBeat

Dec 07, 2025

Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Telehealth Trends - Quiver Quantitative

Dec 07, 2025

Jump Financial LLC Sells 155,479 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat

Dec 07, 2025

Hims & Hers: The Market's Panic Is Irrational (NYSE:HIMS) - Seeking Alpha

Dec 07, 2025

Arrowstreet Capital Limited Partnership Has $28.36 Million Holdings in Hims & Hers Health, Inc. $HIMS - MarketBeat

Dec 07, 2025

Dec 06, 2025